MiR-200c at the nexus of epithelial-mesenchymal transition, resistance to apoptosis, and the breast cancer stem cell phenotype

Breast Cancer Research

Volumn 13, Issue 3, 2011, Pages

  Radisky, Derek C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 200C; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; UNCLASSIFIED DRUG; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; UVOMORULIN;

APOPTOSIS; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER RESEARCH; CANCER STEM CELL; CARCINOGENESIS; EDITORIAL; EPITHELIAL MESENCHYMAL TRANSITION; PHENOTYPE; ANOIKIS; BREAST TUMOR; CELL MOTION; ENDOMETRIUM TUMOR; FEMALE; GENETICS; HUMAN; METABOLISM; NOTE; CELL MOTILITY; GENE EXPRESSION; GENE FUNCTION; PROTEIN EXPRESSION; TUMOR INVASION;

ANOIKIS; BREAST NEOPLASMS; CELL MOVEMENT; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MICRORNAS;

EID: 84860390484     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2885     Document Type: Editorial

References (15)

1. Howe EN, Cochrane DR, Richer JK. Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res 2011, 13:R45. 10.1186/bcr2867, 21501518.
2. O'Day E, Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 2010, 12:201. 10.1186/bcr2484, 2879559, 20346098.
3. Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop - a motor of cellular plasticity in development and cancer?. EMBO Rep 2010, 11:670-677. 10.1038/embor.2010.117, 20706219.
4. Wright JA, Richer JK, Goodall GJ. MicroRNAs and EMT in mammary cells and breast cancer. J Mammary Gland Biol Neoplasia 2010, 15:213-223. 10.1007/s10911-010-9183-z, 20499142.
5. Peter ME. Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 2009, 8:843-852. 10.4161/cc.8.6.7907, 2688687, 19221491.
6. Cochrane DR, Howe EN, Spoelstra NS, Richer JK. Loss of miR-200c: a marker of aggressiveness and chemoresistance in female reproductive cancers. J Oncol 2010, 2010:821717. 2798671, 20049172.
7. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 2009, 8:1055-1066.
8. Chiarugi P, Giannoni E. Anoikis: a necessary death program for anchorage-dependent cells. Biochem Pharmacol 2008, 76:1352-1364. 10.1016/j.bcp.2008.07.023, 18708031.
9. Smit MA, Peeper DS. Zeb1 is required for TrkB-induced epithelial- mesenchymal transition, anoikis resistance and metastasis. Oncogene 2011, [Epub ahead of print], 10.1038/onc.2011.96, 21478908.
10. Schickel R, Park SM, Murmann AE, Peter ME. miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell 2010, 38:908-915. 10.1016/j.molcel.2010.05.018, 20620960.
11. Reiman JM, Knutson KL, Radisky DC. Immune promotion of epithelial- mesenchymal transition and generation of breast cancer stem cells. Cancer Res 2010, 70:3005-3008. 10.1158/0008-5472.CAN-09-4041, 2856111, 20395197.
12. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, Dirbas FM, Somlo G, Pera RA, Lao K, Clarke MF. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009, 138:592-603. 10.1016/j.cell.2009.07.011, 2731699, 19665978.
13. Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell 2010, 39:761-772. 10.1016/j.molcel.2010.08.013, 20832727.
14. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schüler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemnessinhibiting microRNAs. Nat Cell Biol 2009, 11:1487-1495. 10.1038/ncb1998, 19935649.
15. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009, 69:1302-1313. 10.1158/0008-5472.CAN-08-2741, 2819227, 19190339.